Theriva Biologics Inc (TOVX) Stock Analysis
Verdict: AVOID
Investment score: 22/100
Analysis as of
Is Theriva Biologics Inc stock worth reviewing? AI model thesis
A distressed microcap biotech with a cash runway shorter than its clinical timelines.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 35/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Theriva Biologics Inc opportunities and risks
What speaks for TOVX
- Positive VCN-01 Phase 2 Data
What speaks against TOVX
- Imminent Dilution Risk
Peers and competitors
Frequently asked questions about Theriva Biologics Inc (TOVX)
Is TOVX stock a good investment?
The cached TradeMates AI model rates Theriva Biologics Inc as AVOID with an investment score of 22/100. A distressed microcap biotech with a cash runway shorter than its clinical timelines. This is algorithmic model output, not personal investment advice.
Is TOVX stock a buy?
The TradeMates model verdict for TOVX is AVOID with an investment score of 22/100. Treat this as a model signal to review, not a personal buy recommendation.